Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explantation of durable ventricular assist device for myocardial functional recovery in children: A report from the ACTION registry.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Prospective Multicenter Evaluation of a Novel Active Driving System for Pediatric Ventricular Assist Device Support.

Journal of the American College of Cardiology·2026
Same author

Multicenter Registry Analysis of Bivalirudin for Primary Anticoagulation in Pediatric HeartMate 3 Recipients: ACTION Analysis.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Capturing Physiological Data in Children With Heart Failure Using Wearable Digital Technology: Lessons From Pilot Project.

CJC pediatric and congenital heart disease·2026
Same author

Heart Transplantation and Ventricular Assist Device in Duchenne Muscular Dystrophy: A New Era.

Pediatric transplantation·2025
Same author

Authors Insights on the Updated International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014).

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same journal

Aortic Valve Replacement in Women of Reproductive Age.

Journal of the American College of Cardiology·2026
Same journal

Sudden Death in Cardio-Kidney-Metabolic Patients: Insights From FINE-HEART.

Journal of the American College of Cardiology·2026
Same journal

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.

Journal of the American College of Cardiology·2026
Same journal

Reframing Cardiometabolic Risk and Frailty Through Sarcopenic Obesity.

Journal of the American College of Cardiology·2026
Same journal

Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.

Journal of the American College of Cardiology·2026
Same journal

The Measure of a Leader: Lessons in Leadership From Eugene Braunwald.

Journal of the American College of Cardiology·2026
See all related articles

Related Experiment Video

Updated: Jul 15, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.9K

Durable Mechanical Circulatory Support: JACC Scientific Statement.

Ryan J Tedford1, Marzia Leacche2, Angela Lorts3

  • 1Medical University of South Carolina, Charleston, South Carolina, USA.

Journal of the American College of Cardiology
|September 27, 2023
PubMed
Summary
This summary is machine-generated.

Durable left ventricular assist devices (dLVADs) offer improved survival for advanced heart failure patients, approaching 60% at 5 years. However, challenges like delayed referrals hinder wider adoption of this critical therapy.

Keywords:
heart failureheart transplantationleft ventricular assist devicemechanical circulatory support

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K

Related Experiment Videos

Last Updated: Jul 15, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.9K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Advanced heart failure (HF) has poor prognosis with medical therapy alone.
  • Durable left ventricular assist devices (dLVADs) are a crucial option for advanced HF.
  • Recent dLVAD innovations have improved safety profiles and patient survival.

Purpose of the Study:

  • To review contemporary outcomes and challenges associated with dLVAD therapy.
  • To highlight the potential of dLVADs as a bridge to transplantation or destination therapy.
  • To discuss emerging dLVAD technologies.

Main Methods:

  • Review of current literature on dLVAD technology and patient outcomes.
  • Analysis of survival rates and adverse event profiles.
  • Discussion of clinical adoption barriers and future device development.

Main Results:

  • dLVAD support shows 5-year survival rates approaching 60%, comparable to heart transplantation at 2 years.
  • Adverse events like pump thrombosis, stroke, and bleeding have decreased with technological advancements.
  • Significant barriers to dLVAD adoption include delayed patient referral and insufficient clinician awareness of outcomes and quality of life benefits.

Conclusions:

  • dLVAD therapy offers significant survival benefits for advanced heart failure patients.
  • Addressing barriers to referral and improving clinician knowledge are essential for wider dLVAD adoption.
  • Novel, less invasive dLVAD technologies are under development, promising further improvements.